Shanghai Junshi Biosciences Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.85%

Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥600.81 Million

≈ $87.92 Million USD Cash + Short-term Investments

Total Assets

CN¥12.38 Billion

≈ $1.81 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. Check 688180 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688180 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥600.81 Million	4.85%
Total Liquid Assets	CN¥600.81 Million	4.85%

Asset Resilience Insights

Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Akero Therapeutics Inc NASDAQ:AKRO	Biotechnology	55.87%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Zealand Pharma A/S CO:ZEAL	Biotechnology	63.98%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Immunitybio Inc NASDAQ:IBRX	Biotechnology	38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	4.85%	CN¥600.81 Million ≈ $87.92 Million	CN¥12.38 Billion ≈ $1.81 Billion	+0.87pp
2024-12-31	3.99%	CN¥430.51 Million ≈ $63.00 Million	CN¥10.80 Billion ≈ $1.58 Billion	+3.99pp
2020-12-31	0.00%	CN¥17.00K ≈ $2.49K	CN¥8.01 Billion ≈ $1.17 Billion	0.00pp
2019-12-31	0.00%	CN¥17.00K ≈ $2.49K	CN¥4.42 Billion ≈ $647.14 Million	-0.13pp
2018-12-31	0.13%	CN¥5.52 Million ≈ $807.16K	CN¥4.26 Billion ≈ $622.98 Million	-11.96pp
2017-12-31	12.09%	CN¥147.43 Million ≈ $21.57 Million	CN¥1.22 Billion ≈ $178.48 Million	-20.42pp
2016-12-31	32.50%	CN¥373.47 Million ≈ $54.65 Million	CN¥1.15 Billion ≈ $168.14 Million	-38.21pp
2014-12-31	70.71%	CN¥235.44 Million ≈ $34.45 Million	CN¥332.94 Million ≈ $48.72 Million	--

pp = percentage points

About Shanghai Junshi Biosciences Co Ltd

SHG:688180 China Biotechnology

Market Cap

$4.09 Billion

CN¥27.95 Billion CNY

Market Cap Rank

#4009 Global

#583 in China

Share Price

CN¥36.51

Change (1 day)

+2.15%

52-Week Range

CN¥28.93 - CN¥48.80

All Time High

CN¥151.00